Aptamer-based electrochemical nanobiosensor for research and monitoring of multiple sclerosis in mice models.
Autor: | Serin M; Faculty of Pharmacy, Department of Analytical Chemistry, Ege University, 35100 Izmir, Bornova, Turkey; Graduate School of Natural and Applied Sciences, Department of Biomedical Technologies, Ege University, 35100 Izmir, Bornova, Turkey., Kara P; Faculty of Pharmacy, Department of Analytical Chemistry, Ege University, 35100 Izmir, Bornova, Turkey. Electronic address: pinar.kara@ege.edu.tr. |
---|---|
Jazyk: | angličtina |
Zdroj: | Bioelectrochemistry (Amsterdam, Netherlands) [Bioelectrochemistry] 2024 Dec; Vol. 160, pp. 108744. Date of Electronic Publication: 2024 May 19. |
DOI: | 10.1016/j.bioelechem.2024.108744 |
Abstrakt: | Multiple sclerosis (MS) is a severe progressive autoimmune-inflammatory, demyelinating process in the central nervous system (CNS) with heterogeneous neurological symptoms appearing as a consequence of myelin break down. Myelin basic protein (MBP) makes up to 30 % of the CNS myelin [1] and it is known to be released into the cerebrospinal fluid (CSF) as a bioindicator of MS. Autoimmune encephalomyelitis (EAE) is a mice model of MS widely used for research and development of new treatments [2]. Herein, MBP specific aptamer developed for possible therapeutic purposes in mouse model [3] was applied as a bioreceptor for MBP recognition. A nanobiosensor for MBP detection and monitoring was developed by using graphene oxide (GO) nanoparticles integrated onto the screen-printed carbon electrodes (SPCE) and aptamer immobilized to create a bioactive layer on the sensor surface for MBP binding. The measurements were carried out using electrochemical impedance spectrometry (EIS). Validation studies were carried out in a biological matrix (artificial CSF) containing MBP, and MSA. The aptasensor had LOD in artificial CSF 0.01 ng/mL and showed its usability in the concentration range of 0.01 … 64 ng/mL. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |